KB 001 A

Drug Profile

KB 001 A

Alternative Names: Anti-PcrV mAb fragment; KB 001; KB-001A

Latest Information Update: 08 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KaloBios Pharmaceuticals
  • Class Antibacterials; Antibodies; Monoclonal antibodies
  • Mechanism of Action PcrV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pseudomonal infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Nosocomial pneumonia; Pseudomonal infections

Most Recent Events

  • 07 Aug 2017 KaloBios Pharmaceuticals is now called Humanigen
  • 30 Jun 2015 Discontinued - Phase-I for Nosocomial pneumonia (Prevention) and Pseudomonal infections (Prevention) in USA (IV)
  • 30 Jun 2015 Discontinued - Phase-I/II for Nosocomial pneumonia (Prevention) and Pseudomonal infections (Prevention) in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top